Invest now
Mankind Pharma share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹2,399.00(1.27%)October 12, 2026 15:28:50 PM IST
- NSE
- BSE
- Vol : 214.92 K (NSE + BSE)Last 20 day avg : 654.92 K
Mankind Pharma is trading 1.27% upper at Rs 2,399.00 as compared to its last closing price. Mankind Pharma has been trading in the price range of 2,425.05 & 2,359.25. Mankind Pharma has given 7.83% in this year & -6.57% in the last 5 days. Mankind Pharma has TTM P/E ratio 51.44 as compared to the sector P/E of 34.46.There are 16 analysts who have initiated coverage on Mankind Pharma. There are 5 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 568.06 Crores in its last quarter.Listed peers of Mankind Pharma include Sun Pharmaceutical Industries (0.13%), Divi's Laboratories (0.57%), Torrent Pharmaceuticals (0.41%).The Mutual Fund holding in Mankind Pharma was at 10.87% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Mankind Pharma was at 9.45% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 13 Oct 2026, 07:06 AM IST
- BetaLow volatility0.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.39The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation3.66The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Mankind Pharma News
Mankind Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,759.10 | 0.13 | 4,22,067.01 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,379.00 | 0.57 | 2,48,982.98 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,679.00 | 0.41 | 1,77,967.75 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,313.70 | 0.80 | 1,06,128.36 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,139.00 | 2.14 | 1,13,615.69 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allMankind Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-10-26 | Quarterly Results |
| 2026-07-30 | Quarterly Results |
| 2026-05-19 | Audited Results |
| 2026-02-03 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
About the company Mankind Pharma
- IndustryBiotechnology & Drugs
- ISININE634S01028
- BSE Code543904
- NSE CodeMANKIND
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, Rivotril, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
Mankind Pharma Share Price FAQs
Mankind Pharma is trading at 2399.00 as on Mon Oct 12 2026 09:58:50. This is 1.27% upper as compared to its previous closing price of 2369.00.
The market capitalization of Mankind Pharma is 99089.52 Cr as on Mon Oct 12 2026 09:58:50.
The average broker rating on Mankind Pharma is Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 4 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Mankind Pharma is 2640.30 whereas the 52 wk low is 1909.90
Mankind Pharma can be analyzed on the following key metrics -
- TTM P/E: 51.44
- Sector P/E: 34.46
- Dividend Yield: 0.00%
- D/E ratio: -
Mankind Pharma reported a net profit of 1912.93 Cr in 2026.
The Mutual Fund Shareholding was 10.87% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Mankind Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.